Investment Thesis
Nurix Therapeutics is a pre-commercial stage pharmaceutical company with severe operating losses (-$285.7M) and negative free cash flow (-$263.5M), indicating the business model is not yet sustainable. While revenue growth of 54% YoY is positive and the balance sheet shows adequate liquidity ($247M cash, 7.02x current ratio), the company is burning cash at an unsustainable rate and lacks clear profitability visibility.
Strengths
- Strong revenue growth of 54% year-over-year demonstrates market validation
- Adequate liquidity with $247M in cash equivalents and 7.02x current ratio
- No long-term debt, providing financial flexibility and reducing solvency risk
- Substantial asset base of $688.1M supports future operations
Risks
- Extreme operating losses of -$285.7M with operating margin of -340% indicates pre-profitability stage
- Negative free cash flow of -$263.5M means company must continue burning through cash reserves
- At current burn rate, existing cash runway is approximately 12-14 months without additional financing
- Biotech/pharma sector requiring significant R&D investment before commercial viability
- Net loss widening on a percentage basis relative to revenue growth is unsustainable long-term
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway remaining
- Revenue growth sustainability and pipeline advancement toward commercialization
- Gross margin upon achieving scale and operational leverage
- Path to EBITDA breakeven and timeline to profitability
Financial Metrics
Revenue
84.0M
Net Income
-264.5M
EPS (Diluted)
$-3.05
Free Cash Flow
-263.5M
Total Assets
688.1M
Cash
247.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-340.2%
Net Margin
-314.9%
ROE
-49.1%
ROA
-38.4%
FCF Margin
-313.7%
Balance Sheet & Liquidity
Current Ratio
7.02x
Quick Ratio
7.02x
Debt/Equity
0.00x
Debt/Assets
21.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-03T19:24:12.005660 |
Data as of: 2025-11-30 |
Powered by Claude AI